NASDAQ$BLTE

Belite Bio Inc · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

BLTE Q2 2024 — extraction skipped

Belite Bio Inc filed Form 6-K (accession 0001104659-24-096020) for Q2 2024, but headline financial numerics could not be extracted automatically: no headline numerics found by parser nor by Financial Datasets fallback. The row is marked as AI-processed so the queue advances; numerics will be filled by Financial Datasets on its next pass.

  • Form 6-K filed; press release body not parseable here.
  • Reason: no headline numerics found by parser nor by Financial Datasets fallback.
  • Numerics rely on the Financial Datasets fallback.

Headline financials

Total Revenue

$0.00

No prior period
EPS (adj)

-$0.26

Previous: -$0.26+0.0%
Net Income

-$9.49M

No prior period
Operating Income

-$10.5M

No prior period
Gross Profit

$0.00

No prior period

Revenue & EPS history

Belite Bio · Revenue · Quarterly

$0

Q2 2024

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

+0.3%

Avg return

Earnings day

+4.6%

Avg return

5 days after

+3.1%

Avg return

30 days after

31%

4 / 13 earnings

Positive

+36.6%

Q2 2022

Best reaction

-15.2%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-6.5%
Q1 2025-3.4%+3.9%+0.2%
Q4 2024+0.5%-0.2%-15.1%
Q3 2024+4.6%+5.3%-19.4%
Q2 2024-1.4%+1.3%-2.1%
Q1 2024-0.1%+6.9%+18.8%
Q4 2023-15.2%-16.5%-13.6%
Q3 2023-3.7%-5.4%+12.3%
Q2 2023+2.3%+4.2%+39.9%
Q4 2022-3.4%-1.2%-1.9%
Q4 2020-3.4%-1.2%-1.9%
Q4 2021-3.4%-1.2%-1.9%
Q2 2022+36.6%+59.4%+21.7%
Q3 2021
Q2 2021
Q1 2021
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro